Bliss GVS jumps 20% as Anupam Rasayan buys 43%

Stock hits upper circuit after acquisition plan

Bliss GVS Pharma shares hit the 20 percent upper circuit on Tuesday after Anupam Rasayan India announced a plan to acquire up to 43.3 percent stake in the company. The move put the spotlight on a deal that links a specialty chemicals maker with a pharmaceutical formulations company.

During the session, Bliss GVS Pharma was trading at Rs 381.05, up 20 percent. The market reaction followed an exchange filing and subsequent statements outlining the stake purchase price, the deal value, and the funding plan.

What Anupam Rasayan said in its filing

According to Anupam Rasayan India’s exchange filing, the company plans to acquire a 43.3 percent stake in Bliss GVS Pharma at Rs 299 per share. The transaction is estimated at Rs 1,369.51 crore for the 43.3 percent stake.

Alongside the stake acquisition, Anupam Rasayan will also launch a mandatory open offer to purchase an additional 26 percent stake from public shareholders at the same price of Rs 299 per share. The structure signals that the buyer is preparing for a larger shareholding depending on how much of the open offer is subscribed.

Definitive agreement signed, says Managing Director

Anupam Rasayan India Managing Director Anand Desai said the company has entered into a definitive agreement for the transaction. The company also indicated a broader acquisition range, stating it has entered into an agreement to acquire a 43.3 to 48.2 percent equity stake while making an open offer to public shareholders.

The disclosures, made through regulatory filings, provided the key terms that investors typically look for in control-related transactions: the agreed share price, the deal size, and the required open offer component.

Deal size, price and the market reaction

The acquisition price of Rs 299 per share is the stated price for both the negotiated stake purchase and the open offer. On the day of the announcement, Bliss GVS Pharma was trading at Rs 381.05 after hitting the upper circuit.

The gap between the market price during the session and the acquisition price is notable, but the filing did not provide additional detail in the provided text on timelines, conditions precedent, or regulatory steps beyond the open offer requirement.

Funding plan: term loan plus equity instrument

Anand Desai said the acquisition will be funded through a Rs 300 crore term loan. The remaining amount will be raised through a non-controlling, non-voting equity instrument.

This funding mix suggests a combination of debt and an equity-linked instrument that, as described, does not confer control or voting rights. The company did not disclose further details in the provided text on the instrument’s structure, pricing, or investors.

Mandatory open offer: what it means for shareholders

Under the announced plan, Anupam Rasayan will make a mandatory open offer for an additional 26 percent stake from public shareholders at Rs 299 per share. Open offers are designed to provide an exit opportunity to public shareholders when an acquirer crosses specified thresholds.

For shareholders, the key disclosed parameter is the open offer price, which matches the price for the 43.3 percent stake acquisition. The filing does not specify in the provided text when the open offer will open or close.

Transaction snapshot

Why the deal matters for both companies

The update described the transaction as a step that could help boost drug manufacturing and expand market reach. While the provided text does not include operational targets, timelines, or integration plans, the stated intent frames the deal as strategic rather than purely financial.

For Bliss GVS Pharma, a change in significant ownership can influence priorities and access to capital, depending on how the acquisition and open offer play out. For Anupam Rasayan, the deal represents a move beyond specialty chemicals into a pharma formulations business through a large minority stake.

What investors will watch next

The next concrete milestone in such transactions is typically the open offer process and related regulatory documentation. In this case, the company has already stated that a mandatory open offer for an additional 26 percent will be launched at Rs 299 per share.

Investors are also likely to track further disclosures on the definitive agreement, including any conditions, closing steps, and whether the stake ultimately lands closer to the 43.3 percent level or the 48.2 percent figure mentioned by the company.

Conclusion

Bliss GVS Pharma’s 20 percent upper-circuit move followed Anupam Rasayan India’s announcement to acquire up to 43.3 percent at Rs 299 per share for Rs 1,369.51 crore and to make an open offer for another 26 percent at the same price. The acquisition is planned to be funded through a Rs 300 crore term loan and the rest via a non-controlling, non-voting equity instrument, with further steps expected through the open offer process and subsequent regulatory updates.